U.S. Markets open in 21 mins

Complimentary Technical Snapshots on Teva Pharma Industries and Three More Drug Makers Stocks

Stock Research Monitor: DEPO, DRRX, and ENDP

LONDON, UK / ACCESSWIRE / July 9, 2018 / If you want a free Stock Review on TEVA sign up now at www.wallstequities.com/registration. In today's pre-market research, WallStEquities.com features four Drug Manufacturers stocks, namely: Teva Pharmaceutical Industries Ltd (NYSE: TEVA), Depomed Inc. (NASDAQ: DEPO), DURECT Corp. (NASDAQ: DRRX), and Endo International PLC (NASDAQ: ENDP). The pharmaceutical manufacturing sector consists of establishments that are primarily engaged in one or more of the following: manufacturing biological and medical products; processing botanical drugs and herbs; isolating active medical principles from botanical drugs and herbs; and manufacturing pharmaceutical products intended for internal and external consumption. All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

Teva Pharmaceutical Industries

Petach Tikva, Israel headquartered Teva Pharmaceutical Industries Ltd's stock finished last Friday's session 0.88% higher at $24.13. A total volume of 7.84 million shares was traded. The Company's shares have advanced 10.69% in the past month and 42.95% over the previous three months. The stock is trading above its 50-day and 200-day moving averages by 11.80% and 31.41%, respectively. Additionally, shares of Teva Pharma, which develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide, have a Relative Strength Index (RSI) of 60.67.

On June 15th, 2018, Teva Pharma announced a change in the ENFORCE Phase-III clinical development program of fremanezumab in chronic cluster headache. A pre-specified futility analysis of the chronic cluster headache study revealed that the primary endpoint of mean change from baseline in the monthly average number of cluster headache attacks during the 12-week treatment period is unlikely to be met. There were no safety concerns observed with fremanezumab treatment in the trial.

On June 27th, 2018, research firm Citigroup reiterated its ‘Buy' rating on the Company's stock with an increase of the target price from $25 a share to $27 a share. Get the full research report on TEVA for free by clicking below at:

www.wallstequities.com/registration/?symbol=TEVA

Depomed

On Friday, shares in Newark, California headquartered Depomed Inc. ended the session 0.85% lower at $6.99. The stock recorded a trading volume of 441,308 shares. The Company's shares have gained 8.88% in the last month and 6.23% in the previous three months. The stock is trading 2.99% above its 50-day moving average and 2.74% above its 200-day moving average. Moreover, shares of Depomed, which engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the US, have an RSI of 54.23. Access the free research report on DEPO now by signing up at:

www.wallstequities.com/registration/?symbol=DEPO

DURECT

Cupertino, California headquartered DURECT Corp.'s shares dropped 3.55%, closing the session at $1.63 with a total trading volume of 763,228 shares. The stock has gained 5.84% over the past year. The stock is trading 4.60% above their 200-day moving average. Additionally, shares of DURECT, which researches and develops medicines based on its epigenetic regulator and drug delivery programs, have an RSI of 36.05.

On June 26th, 2018, DURECT reported that a joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee of the US FDA voted 14 to three against the approval of REMOXY® ER (oxycodone extended-release capsules) for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. The Prescription Drug User Fee Act date for completion of the review is August 07th, 2018. Are you already registered with Wall St. Equities? Do so now for free, and get the report on DRRX at:

www.wallstequities.com/registration/?symbol=DRRX

Endo International

Last Friday at the close, shares in Dublin, Ireland headquartered Endo International PLC recorded a trading volume of 6.45 million shares, which was above their three months average volume of 6.35 million shares. The stock ended the session 7.31% higher at $10.86. The Company's shares have surged 40.13% in the past month and 97.81% over the previous three months. The stock is trading above its 50-day and 200-day moving averages by 48.88% and 51.36%, respectively. Furthermore, shares of Endo International, which manufactures and sells generic and branded pharmaceuticals in the US, Canada, and internationally, have an RSI of 80.73.

On June 27th, 2018, research firm Citigroup upgraded the Company's stock rating from ‘Neutral' to ‘Buy'.

On July 02nd, 2018, Endo International ("ENDP") announced that one of its operating companies, Par Pharmaceutical, Inc. ("Par"), has begun shipping an authorized generic version of Takeda Pharmaceutical's Colcrys® (colchicine, USP) 0.6 mg tablets. ENDP's subsidiary, Endo Ventures Limited, entered into an exclusive US supply and distribution agreement with Takeda Pharmaceuticals USA, allowing Par to launch and distribute an authorized generic of the product. Aspiring Member, please take a moment to register below for your free research report on ENDP at:

www.wallstequities.com/registration/?symbol=ENDP

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com

Phone number: 21 32 044 483

Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities